May 24, 2020
TG4050 is being evaluated in two Phase 1 clinical trials. It combines Transgene's proprietary myvac platform with NEC's cutting-edge Artificial Intelligence (AI) capabilities to select patient-specific neoantigens – Data confirm that the prediction algorithm successfully identifies immunogenic cancer mutations, even among a large set of candidate mutations – Data will […]